A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the organisation for economic co-operation and development

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Barnieh, Lianne ^a   Clement, Fiona ^b   Harris, Anthony ^c   Blom, Marja ^d   Donaldson, Cam ^e   Klarenbach, Scott ^f   Husereau, Don ^g   Lorenzetti, Diane ^b   Manns, Braden ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF HELSINKI   (Finland)

^e GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^f UNIVERSITY OF ALBERTA   (Canada)

^g UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; AGE; ARTICLE; CHRONIC DISEASE; COST MINIMIZATION ANALYSIS; DATA PROCESSING; DRUG COST; EMPLOYMENT STATUS; FINANCIAL MANAGEMENT; FUNDING; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH INSURANCE; INCOME; PRACTICE GUIDELINE; PRESCRIPTION; PRESCRIPTION DRUG INSURANCE; SOCIAL STATUS; SYSTEMATIC REVIEW; CLINICAL PRACTICE; COST; DRUG UTILIZATION; HUMAN; META ANALYSIS; ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT;

PRESCRIPTION DRUG;

COST SHARING; DRUG UTILIZATION; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTION DRUGS;

EID: 84897506541     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090434     Document Type: Article

References (127)

1. Organisation of Economic Cooperation and Development (2012) OECD Health Data 2012 - Frequently Requested Data. Available: http://www.oecd.org/health/ healthpoliciesanddata/oecdhealthdata2012- frequentlyrequesteddata.htm. Accessed: 2012 April 5
2. Ess S, Schneeweiss S, Szucs T (2003) European healthcare policies for controlling drug expenditure. Pharmacoeconomics 21: 89-103. (Pubitemid 36127005)
3. Canadian Institute for Health Information (2007) Canadian Institute for Health Information: Drug expenditure in Canada, 1985 to 2006. Ottawa: CIHI.
4. Lu M, Jonsson E, editors (2008) Financing health care: New ideas for a changing society. Weinheim, Germany: Wiley-VCH.
5. PPRI secretariat (2007) Pharmaceutical Pricing and Reimbursement Information. Vienna, Austria.
6. Rapoport J, Jacobs P, Jonsson E, editors (2009) Cost containment and efficiency in national health systems. Weinheim, Germany: Wiley-VCH.
7. Daw J, Morgan S (2012) Stitching the gaps in the Canadian public drug coverage patchwork? A review of provincial pharmacare policy changes from 2000 to 2010. Health Policy 104: 19-26.
8. Duerden M, Gogna N, Godman B, Eden K, Mallinson M, et al. (2004) Current national initiatives and policies to control drug costs in Europe: UK perspective. J Ambulatory Care Management 27: 132-138. (Pubitemid 38365352)
9. Yoongthong W, Hu S, Whitty J, Wibulpolprasert S, Sukantho K, et al. (2012) National drug policies to local formulary decisions in Thailand, China, and Australia: drug listing changes and opportunities. Value in Health 15: S126-131.
10. Leopold C, Habl C (2008) Pharmaceutical Pricing and Reimbursement Information: Austria. Vienna: Gesundheit Osterreich GmbH/Geschaftsbereich OBIG (GOG/OBIG).
11. Prescription d'un pourcentage minimum de médicaments bon marché. Available: http://www.riziv.fgov.be/care/fr/doctors/promotion- quality/feedbacks/feedback-generica/index.htm Last accessed: 2013 June 4.
12. Vogler S, Zimmermann N, Leopold C, de Joncheere K (2011) Pharmaceutical policies in European countries in response to the global financial crisis. Southern Med Review 4: 22-32.
13. Joyce G, Escarce J, Solomon M, Goldman D (2002) Employer drug benefit plans and spending on prescription drugs. JAMA 288: 1733-1739.
14. Goldman D, Joyce G, Karaca-Mandic P (2006) Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. Am J Manag Care 12: 21-28. (Pubitemid 43139537)
15. Brook R, Ware J, Rogers W, Keeler E, Davies A, et al. (1983) Does free care improve adults' health? N Engl J Med 309: 1426-1435.
16. Tamblyn R, Laprise R, Hanley J, Abrahamowicz M, Scott S, et al. (2001) Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 285: 421-429. (Pubitemid 32097260)
17. Solomon M, Goldman D, Joyce G, Escarce J (2009) Cost sharing and the initiation of drug therapy for the chronically ill. Archives Internal Medicine 169: 740-748.
18. Doshi J, Zhu J, Lee B, Kimmel S, Volpp K (2009) Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation 119: 390-397.
19. Gibson T, Mark T, Axelsen K, Baser O, Rublee D, et al. (2006) Impact of statin copayments on adherence and medical care utlization and expenditures. Am J Manag Care 12: SP11-19. (Pubitemid 46053391)
20. Choudhry N, Avorn J, Glynn R, Antman E, Schneeweiss S, et al. (2011) Full coverage for preventive medications after myocardial infarction. N Engl J Med 365: 2088-2097.
21. Goldman D, Joyce G, Zheng Y (2007) Prescription drug cost sharing: Associations with medication and medical utilization and spending and health JAMA 298: 61-69. (Pubitemid 47026771)
22. Dormuth C, Glynn R, Neumann P, Maclure M, Brookhart A, et al. (2006) Impact of two seequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma. Clin Ther 28: 964-978. (Pubitemid 44062695)
23. Dormuth C, Neumann P, Maclure M, Glynn R, Schneeweiss S (2009) Effects of prescription coinsurance and income-based deductibles on net health plan spending for older users of inhaled medications. Med Care 47: 508-516.
24. Hynd A, Roughead E, Preen D, Glover J, Bulsara M, et al. (2008) The impact of co-payment increases on dispensings of government-subsidised medicines in Australia. Pharmacoepidemiol Drug Saf 17: 1091-1099.
25. Liu S-Z, Romeis J (2004) Changes in drug utilization following the outpaitent prescription drug cost-sharing program- evidence from Taiwan's elderly. Health Policy 68: 277-287. (Pubitemid 38534456)
26. Joyce G, Goldman D, Karaca-Mandic P, Zheng Y (2007) Pharmacy benefit caps and the chronically ill. Health Affairs 26: 1333-1343.
27. Drummond M, Towse A (2012) Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe? Eur J Health Econ 13: 1-5.
28. Durand-Zleski I, Colin C, Blum-Boisgard C (1997) An attempt to save money by using mandatory practice guidelines in France. BMJ 315: 943-946. (Pubitemid 27425130)
29. Durieux P, Chaix-Couturier C, Durand-Zleski I, Ravaud P (2000) From clinical recommendations to mandatory practice. The introduction of regulatory practice guidelines in the French healthcare system. International Journal of Technology Assessment in Health Care 16: 969-975.
30. Fretheim A, Havelsrud K, MacLennan G, Kristoffersen D, Oxman A (2007) The effects of mandatory prescribing of thiazides for newly treated, uncomplicated hypertension: interrupted time-series analysis. PLOS Med 4: e232.
31. Käypä hoito (2012) Current Care Guidelines. Available: http://www.kaypahoito.fi/web/kh/etusivu. Last accessed: 2012 April 5.
32. Sweeny K (2009) The impact of copayments and safety nets on PBS expenditure. Australian Health Review 33: 215-231.
33. Austvoll-Dahlgren A, Aaserud M, Vist G, Ramsay C, Oxman A, et al. (2009) Pharmaceutical policies: effects of cap and co-payment on rational drug use. Cochrane Database of Systematic Reviews.
34. Department of Health and Ageing (2008) Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.3). Canberra.
35. Streat S, Munn S (2012) Health economics and health technology assessment: Perspectives from Australia and New Zealand. Crit Care Clin 28: 125-133.
36. Lopert R (2009) Evidence-based decision-making within Australia's pharmaceutical benefits scheme. Issue Brief (Commonw Fund) 60: 1-13.
37. Department of Health and Aged Care (2000) The Australian Health Care System: An Outline. Canberra
38. Wild C (2009) Austria: History of health techcnology assessment during the past 20 years. International Journal of Technology Assessment in Heatlh Care 25: 74-81.
39. Godman B, Bucsics A, Burkhardt T, Haycox A, Seyfriend H, et al. (2008) Insight into recent reforms and initiatives in Austria: Implications for key stakeholders. Expert Review of Pharmacoeconomics and Outcomes Research 8: 357-371.
40. Walter E, Zehetmayr S (2006) Guidelines on Health Economic Evaluaion: Consensus paper. Vienna: Institut fur Pharmaokonomische Forschung.
41. Gerkens S, Merkur S (2010) Belgium: Health System Review. European Observatory on Health Systems and Policies.
42. Cleemput I, Crott R, Vrijens F, Huybrechts M, van Wilder P, et al. (2006) Guidelines for pharmaco-economic evaluations in Beligum Brussels: Centre federal d'expertise des soins de sante.
43. Cleemput I, van Wilder P, Huybrechts M, Vrijens F (2009) Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests. Value in Health 12: 441-449.
44. DeSwaef A, Antonissen Y (2008) Pharmaceutical Pricing and Reimbursement Information: Belgium. Vienna: Gesundheit Osterreich GmbH/Geschaftsbereich OBIG (GOG/OBIG).
45. Garattini L, Cornago D, De Compadri P (2007) Pricing and reimbursement of in-patent drugs in seven European counries: A comparative analysis. Health Policy 82: 330-339. (Pubitemid 46962794)
46. Canadian Treatment Action Council (2007) Generic drugs in Canada: A policy paper. World Health Stratigies.
47. Canadian Agency for Drugs and Technologies in Health (2006) Guidelines for the economic evaluation of health technologies: Canada. Ottawa.
48. Paris V, Docteur E (2006) Pharmaceutical pricing and reimbursement policies in Canada. Organisation for Economic Co-operation and Development.
49. Canadian Agency for Drugs and Technologies in Health (2010) Procedure for common drug review. Ottawa.
50. Demers V, Mela M, Jackevicius C, Cox J, Kalavrouziotois D, et al. (2008) Comparison of provincial prescription drug plans and the impact on patients' annual drug expenditures. CMAJ 178: 405-409. (Pubitemid 351303282)
51. Menon D, Stafinski T (2009) Health technology assessment in Canada: 20 years strong? Value in Health 12: S14-19.
52. Bryndova L, Pavlokova K, Roubal T, Rokosova M, Gaskins (2009) Czech Republic: Health System Review. European Observatory on Health Systems and Policies. 1-122 p.
53. Davidova J, Praznovcova L, Lundborg C (2008) Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden. Pharm World Sci 30: 57-64. (Pubitemid 350172648)
54. Strandberg-Larsen M, Nielsen M, Vallgarda S, Krasnik A, Vrangbaek K (2007) Denmark: Health System Review. European Observatory on Health Systems and Policies. 1-164 p.
55. Thomsen E, Er S, Rasmussen P (2008) Pharmaceutical Pricing and Reimbursement Information: Denmark. Vienna: Gesundheit Osterreich GmbH/Geschaftsbereich OBIG (GOG/OBIG).
56. National Institute for Health and Clinical Excellence (2008) Guide to the methods of technology appraisal.
57. Palnoch D, Kullman D, Sherriff J, Barnor E, Baxter M, et al. (2007) Pharmaceutical Pricing and Reimbursement Information: United Kingdom. Vienna: Gesundheit Osterreich GmbH/Geschaftsbereich OBIG (GOG/OBIG).
58. Rawlins M, Barnett D, Stevens A (2010) Pharmacoeconomics: NICE's approach to decision-making. Br J Clin Pharmacol 70: 346-349.
59. Chalkidou K (2009) Comparative effectiveness review within the U.K.'s National Institute for Health and Clinical Excellence. Issue Brief (Commonw Fund) 59: 1-12.
60. Pudersell K, Vetka A, Rootslane L, Mathiesen M, Vendla K, et al. (2007) Pharmaceutical Pricing and Reimbursement Information: Estonia. Vienna: Gesundheit Osterreich GmbH/Geschaftsbereich OBIG (GOG/OBIG).
61. Kanavos P, Vandoros S, Habicht J, de Johncheere K (2009) Review of the Estonian pharmaceutical sector: Towards the development of a national medicines policy. Copenhagen: World Health Organization.
62. Finnish Medicines Agency and Social Insurance Institution (2011) Finnish statistics on medicines 2010. Helsinki.
63. Peura S, Rajaniemi S, Kurkijarvi U (2007) Pharmaceutical Pricing and Reimbursement Information: Finland. Vienna: Gesundheit Osterreich GmbH/Geschaftsbereich OBIG (GOG/OBIG).
64. Vuorenkoski L (2008) Finland: Health System Review. European Observatory on Health Systems and Policies. 1-122 p.
65. Van Ganse E, Chamba G, Bruet G, Becquart V, Stamm C, et al. (2008) Pharmaceutical Pricing and Reimbursement Information: France. Vienna: Gesundheit Osterreich GmbH/Geschaftsbereich OBIG (GOG/OBIG).
66. Sermet C, Andrieu V, Godman B, Van Ganse E, Haycox A, et al. (2010) Ongoing pharmaceutical reforms in France. Appl Health Econ Health Policy 8: 7-24.
67. Rochaix L, Xerri B (2009) National Authority for Health: France. Issue Brief (Commonw Fund) 58: 1-9.
68. Nasser M, Sawicki P (2009) Institute for Quality and Efficiency in Health Care: Germany. Issue Brief (Commonw Fund) 57: 1-12.
69. von der Schulenberg J, Prenzler A, Schurer W (2010) Cancer management and reimbursement aspects in Germany: an overview demonstrated by the case of colorectal cancer. Eur J Health Econ 10: S21-26.
70. Stargardt T, Busse R (2008) Pharmaceutical Pricing and Reimbursement Information: Germany. Vienna: Gesundheit Osterreich GmbH/Geschaftsbereich OBIG (GOG/OBIG).
71. Bekkering G, Kleijnen J (2008) Procedures and methods of benefit assessments for medicines in Germany. Eur J Health Econ 9: S5-29.
72. Fricke F, Dauben H (2009) Health technology assessment: A perspective from Germany. Value in Health 12: S20-27.
73. Vardica A, Kontozamanis V (2007) Pharmaceutical Pricing and Reimbursement Information: Greece. Vienna: Gesundheit Osterreich GmbH/Geschaftsbereich OBIG (GOG/OBIG).
74. Yfantopoulos J (2008) Pharmaceutical pricing and reimbursement reforms in Greece. Eur J Health Econ 9: 87-97.
75. Kovacs T, Rozsa P, Szigeti S, Borcsek B, Lengyel G (2007) Pharmaceutical Pricing and Reimbursement Information: Hungary. Vienna: Gesundheit Osterreich GmbH/Geschaftsbereich OBIG (GOG/OBIG).
76. Dasbach E, Nagy L, Brandtmuller A, Elbasha E (2010) The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/6/18) in Hungary. Journal of Medical Economics 13: 110-118.
77. Halldorsson M (2003) Health care systems in transition: Iceland. Copenhagen.
78. Barry M (2008) Economics in drug usage in the Irish healthcare setting.
79. McDaid D, Wiley M, Maresso A, Mossialos E (2009) Ireland: Health system review. Health Systems in Transition 11: 1-268.
80. Tilson L, Barry M (2010) Recent developments in pharmacoeconomics evaluation in Ireland. Expert Review of Pharmacoeconomics and Outcomes Research 10: 221-224.
81. Elliott D, Byrne G (2007) Pharmaceutical Pricing and Reimbursement Information: Ireland. Vienna: Gesundheit Osterreich GmbH/Geschaftsbereich OBIG (GOG/OBIG).
82. Barry M, Usher C, Tilson L (2010) Public drug expenditure in the Republic of Ireland. Expert Rev Pharmacoeconomics Outcomes Res 10: 239-245.
83. Barry M, Tilson L (2007) Recent developments in pricing and reimbursement of medicines in Ireland. Expert Rev Pharmacoeconomics Outcomes Res 7: 605-611.
84. Shani S, Siebzehner M, Luxenburg O, Shemer J (2000) Setting priorities for the adoption of health technologies on a national level - the Israeli experience. Health Policy 54: 169-185. (Pubitemid 32012607)
85. Greenberg D, Siebzehner M, Pliskin J (2009) The process of updating the National List of Health Services in Israel: Is it legitimate? Is it fair. International Journal of Technology Assessment in Health Care 25: 255-261.
86. Folino-Gallo P, Montilla S, Bruzzone M, Martini N (2008) Pricing and reimbursement of pharmaceuticals in Italy. Eur J Health Econ 9: 305-310.
87. Lo Scalzo A, Donatini A, Orzella L, Cicchetti A, Profili S, et al. (2009) Italy: Health system review. 1-216 p.
88. Martini N, Folino-Gallo P, Montilla S (2007) Pharmaceutical Pricing and Reimbursement Information: Italy. Vienna: Gesundheit Osterreich GmbH/Geschaftsbereich OBIG (GOG/OBIG).
89. Liu G, Fukuda T, Lee C, Chen V, Zheng Q, et al. (2009) Evidence-based decision-making on medical technologies in China, Japan, and Singapore. Value in Health 12: S12-17.
90. Tatara K, Okamoto E (2009) Japan: Health system review. Health Systems in Transition 11: 1-164.
91. Iizuka T (2008) The economics of pharmaceutical pricing and physician prescribing in Japan: Aoyama Gakuin University.
92. Nakao S, Kawabe H, Takuma H, Shiragami M (2010) Acceptable incremental cost effectiveness ratio for use of new drugs, case in statin therapies. Yakugaku Zasshi 130: 1347-1352.
93. Kamae I (2010) Value-based approaches to healthcare systems and pharmacoeconomics requirements in Asia. South Korea, Taiwan, Thailand and Japan. Pharmacoeconomics 28: 831-838.
94. Habl C, Antony K, Arts D, Entleitner M, Froschl B, et al. (2006) Surveying, assessing and analysing the pharmaceutical sector in the 25 EU member states. Luxembourg: European Commission.
95. Caisse Nationale de la Sante (2011) Formulaires d'inscription dans la liste positive.
96. Oortwijn W, Mathijissen J, Banta D (2010) The role of health technology assessment in selected middle-income countries. Health Policy 95: 174-184.
97. Moise P, Docteur E (2007) Pharmaceutical pricing and reimbursement policies in Mexcio. Paris: OECD.
98. Schafer W, Kroneman M, Boerma W, van den Berg M, Westert G, et al. (2010) The Netherlands: Health system review. Health Systems in Transition 12: 1-229.
99. Raftery J (2008) Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand. Med J Aus 188: 26-28.
100. Cumming J, Mays N, Daube J (2010) How New Zealand has contained expenditure on drugs. BMJ 340: c2441.
101. Sundakov A, Sundakov V (2005) New Zealand pharmaceutical policies: Time to take a fresh look. Castalia Strategic Advisors.
102. Festoy H, Sveen K, Yu L-M, Gjonnes L, Gregersen T (2008) Pharmaceutical Pricing and Reimbursement Information: Norway. Vienna: Gesundheit Osterreich GmbH/Geschaftsbereich OBIG (GOG/OBIG).
103. Kuszewski K, Gericke C (2005) Health systems in transition: Poland. Copenhagen: WHO Regional Office for Europe on behalf of the European Observatory on Health Systems and Policies.
104. Janiszewski R, Bondaryk K (2007) Pharmaceutical Pricing and Reimbursement Information: Austria. Vienna: Gesundheit Osterreich GmbH/Geschaftsbereich OBIG (GOG/OBIG).
105. Kazakov R (2007) Pricing and reimbursement policies in new EU accession countries. Journal of Generic Medicines 4: 249-259.
106. Barros P, de Almeida Simoes J (2007) Portugal: Health system review. Health Systems in Transition 9: 1-140.
107. Teixeira I, Vieira I (2008) Pharmaceutical Pricing and Reimbursement Information: Portugal. Vienna: Gesundheit Osterreich GmbH/Geschaftsbereich OBIG (GOG/OBIG).
108. Mazag J, Segec A (2007) Pharmaceutical Pricing and Reimbursement Information: Slovakia. Vienna: Gesundheit Osterreich GmbH/Geschaftsbereich OBIG (GOG/OBIG).
109. Kalo Z, Paris V, Docteur E (2008) Pharmaceutical pricing and reimbursement policies in Slovakia. Organisation for Economic Co-operation and Development.
110. Albreht T, Turk E, Toth M, Ceglar J, Marn S, et al. (2009) Slovenia: Health system review. Health Systems in Transition 11: 1-168.
111. Jirawattanapisal T, Kingkaew P, Lee T, Yang M (2009) Evidence-based decision-making in Asia-Pacific with rapidly changing health-care systems: Thailand, South Korea, and Taiwan. Value in Health 12: S4-11.
112. Bae E, Lee E (2009) Pharmacoeconomic guidelines and theier implementation in the positive list system in South Korea. Value in Health 12: S36-41.
113. Chun C, Kim S, Lee J, Lee S (2009) Republic of Korea: Health system review. Health Systems in Transition 11: 1-184.
114. Yang B-M, Bae E, Kim J (2008) Economic evaluation and pharmaceutical reimbursement reform in South Korea's National Health Insurance. Health Affairs 27: 179-187. (Pubitemid 351198603)
115. Park S, Lim S, Choi H, Lee S, Kim D, et al. (2012) Evaluation on the first 2 years of the positive list system in South Korea. Health Policy 104: 32-39.
116. Ngorsuraches S, Meng W, Kim B, Kulsomboon V (2012) Drug reimbursement decision-making in Thailand, China, and South Korea. Value in Health 15: S120-125.
117. Duran A, Lara J, van Waveren M (2006) Spain: Health system review. Health Systems in Transition 8: 1-208.
118. Vogler S, Espin J, Habl C (2009) Pharmaceutical pricing and reimbursement information (PPRI) - new PPRI analysis including Spain. Pharmaceuticals Policy and Law 11: 213-234.
119. Anell A, Persson U (2005) Reimbursement and clinical guidance for pharmaceuticals in Sweden. Eur J Health Econ 50: 274-279.
120. Glenngard A, Hjalte F, Svensson M, Anell A, Bankauskaite V (2005) Health systems in transition: Sweden. Copenhagen: WHO Regional Office for Europe on behalf of the European Observatory on Health Systems and Policies.
121. Moise P, Docteur E (2007) Pharmaceutical pricing and reimbursement policies in Sweden. Paris: OECD.
122. Pharmaceutical Benefits Board L (2007) The Swedish pharmaceutical reimbursement system.
123. Redman T, Hoggard M (2007) Pharmaceutical Pricing and Reimbursement Information: Sweden. Vienna: Gesundheit Osterreich GmbH/Geschaftsbereich OBIG (GOG/OBIG).
124. Paris V, Docteur E (2007) Pharmaceutical pricing and reimbursement policies in Switzerland. Paris: OECD.
125. Decollogny A, Eggli Y, Halfon P, Lufkin (2011) Determinants of generic substitution in Switzerland. BMC Health Services Research 11.
126. Tatar M (2007) Pharmaceutical Pricing and Reimbursement Information: Turkey. Vienna: Gesundheit Osterreich GmbH/Geschaftsbereich OBIG (GOG/OBIG).
127. Balfour D, Evans S, Januska J, Lee H, Lewis S, et al. (2009) Medicare Part D - A roundtable discussion of current issues and trends. Journal of Managed Care Pharmacy 15: S3-9.